Acyclovir derivatives and other new antiviral agents

Seminars in Pediatric Infectious Diseases

Volumn 12, Issue 3, 2001, Pages 224-234

  Kimberlin, David W ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR DERIVATIVE; AMINOGLYCOSIDE; AMPHOTERICIN B; ANTIVIRUS AGENT; CIDOFOVIR; FAMCICLOVIR; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; VALACICLOVIR; VANCOMYCIN;

ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; HEADACHE; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA; META ANALYSIS; NAUSEA; NEPHROTOXICITY; PROTEIN SYNTHESIS; RETINITIS; VIRUS INFECTION; VIRUS REPLICATION;

EID: 0034934753     PISSN: 10451870     EISSN: None     Source Type: Journal    
DOI: 10.1053/spid.2001.24097     Document Type: Article

References (70)

1. New modalities for preventing and treating influenza
2. Intracellular metabolism of the antiherpes agent (s)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine
3. Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir
4. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents
5. Sensitivities of human cytomegalovirus (HCMV) clinical isolates to cidofovir
6. Comparative activity of selected antiviral compounds against clinical isolates of human cytomegalovirus
7. The studies of ocular complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group: Cidofovir (HPMPC) for the treatment of cytomegalovirus retinitis in patients with AIDS: The HPMPC peripheral cytomegalovirus retinitis trial
8. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial
9. Intralesional cidofovir for recurrent respiratory papillomatosis in children
10. Juvenile onset recurrent respiratory papillomatosis: Possibilities for successful antiviral therapy
11. Molecular mechanisms of antiviral resistance
12. Famciclovir for the treatment of acute herpes zoster: Effects on acute disease and postherpetic neuralgia: A randomized, double-blind, placebo-controlled trial
13. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes: A randomized, double-blind, multicenter trial
14. Oral famciclovir for the suppression of recurrent genital herpes: A randomized controlled trial
15. Penciclovir cream for the treatment of sunlight-induced herpes simplex labialis: A randomized, double-blind, placebo-controlled trial
16. Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment
17. Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922)
18. Fomivirsen
19. Fomivirsen - A phosphorothioate oligonucleotide for the treatment of CMV retinitis
20. Foscarnet-resistant herpes simplex virus infection in patients with AIDS
21. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC)
22. Antiviral resistance in clinical practice
23. Studies of ocular complications of AIDS Research Group: Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis
24. Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients
25. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS
26. Foscarnet in the treatment of cytomegalovirus infection of the esophagus and colon in patients with the acquired immune deficiency syndrome
27. Treatment of acquired immune deficiency syndrome (AIDS)-related pneumonia with foscarnet: A double-blind placebo controlled study
28. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS
29. Foscarnet nephrotoxicity: Mechanism, incidence and prevention
30. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir
31. Activity of 9-(1,3-dihydroxy-2-propoxymethyl)guanine compared with that of acyclovir against human, monkey, and rodent cytomegaloviruses
32. Molecular detection of human cytomegalovirus and determination of genotypic ganciclovir resistance in clinical specimens
33. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection
34. Human pharmacokinetics of the antiviral drug DHPG
35. Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections
36. Human pharmacokinetics and tolerance of oral ganciclovir
37. Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: Implications for therapy
38. Induction and maintenance therapy of cytomegalovirus central nervous system infection in HIV-infected patients
39. Ganciclovir resistance and UL97 gene mutations in cytomegalovirus blood isolates from patients with AIDS treated with ganciclovir
40. Ganciclovir treatment of cytomegalovirus colitis in AIDS: A randomized, double-blind, placebo-controlled multicenter study
41. Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients
42. Activity of 9-[(2-hydroxy-1-(hydroxymethyl)ethoxymethyl)] guanine in the treatment of cytomegalovirus pneumonia
43. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants
44. Preemptive therapy in CMV-antigen positive patients after liver transplantation-A prospective trial
45. Comparison of the efficacy and cost effectiveness of preemptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients
46. Preemptive treatment for the prevention of cytomegalovirus disease in lung and heart transplant recipients
47. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation
48. Ganciclovir prophylaxis for cytomegalovirus infections in pulmonary allograft recipients
49. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation
50. Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with CMV-seropositive donors
51. Ganciclovir (GCV) treatment of symptomatic congenital cytomegalovirus (CMV) infections: Results of a phase III randomized trial
52. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS
53. Pharmacokinetics of ganciclovir in a patient undergoing hemodialysis
54. Valaciclovir (BW256U87): The L-valyl ester of acyclovir
55. Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy
56. Mechanism of action and selectivity of acyclovir
57. Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate
58. Herpes simplex virus type 2 meningoencephalitis resistant to acyclovir in a patient with AIDS
59. Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes, and mouth: Results of a phase I/II trial
60. Brief report: Recurrent acyclovir-resistant genital herpes in an immunocompetent patient
61. Acyclovir resistant varicella zoster and HIV infection
62. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans
63. Pharmacokinetics of the acyclovir prodrug, valaciclovir, after escalating single- and multiple-dose administration to normal volunteers
64. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults
65. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial
66. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis
67. A randomized, placebo-controlled comparison of oval valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections
68. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: A large-scale dose range-finding study
69. Valacyclovir effective for suppression of recurrent HSV-1 herpes labialis
70. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204)